ATOS Atossa Genetics Inc.

Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020
EN
07/10/2020

Underlying

ATOSAtossa Genetics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atossa Genetics Inc.

Free Trial
ATOS Atossa Genetics...

Atossa Therapeutics Inc: 1 director

A director at Atossa Therapeutics Inc maiden bought 25,000 shares at 1.770USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

ATOS ATOSSA GENETICS INC.
04/12/24 April 12, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Genetics...

Atossa Therapeutics Announces First Quarter 2023 Financial Results and...

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter 2023 with $103.9 million of cash and cash equivalents and no debt SEATTLE, May 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs...

May 15, 2023 1 EN
 PRESS RELEASE
Free
ATOS Atossa Genetics...

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast...

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces that a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- brea...

May 9, 2023 1 EN
 PRESS RELEASE
Free
ATOS Atossa Genetics...

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Re...

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment” Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at ATOS5423.TribePublic.com SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in oncology with a current focus on breast c...

April 27, 2023 1 EN
 PRESS RELEASE
Free
ATOS Atossa Genetics...

Atossa Therapeutics Announces Year-End 2022 Financial Results and Prov...

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments. Key developments from Q4 2022 and year to date include: Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELIN...

March 22, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch